QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan
Table 1
Clinical characteristics of patients with inflammatory bowel disease.
Characteristics
Total IBD ()
CD ()
UC ()
value (CD vs. UC)
Male gender, (%)
97 (75)
54 (76)
43 (73)
0.832
Diagnostic mean age (years) (SD)
37.18 (15.96)
36.18 (17.46)
38.37 (14.01)
0.429
Mean age at biological agent (years) (SD)
41.12 (15.91)
39.18 (16.81)
43.44 (14.56)
0.124
Mean follow-up period (months) (SD)
32.1 (24.19)
44.15 (25.28)
17.59 (11.74)
<0.001
BMI (kg/m2), mean (SD)
21.8 (4.07)
21.09 (3.92)
22.69 (4.11)
0.028
Smoking
No smoking, (%)
84 (65)
43 (61)
41 (69)
0.381
Ex-smoking and current smoking, (%)
46 (35)
28 (39)
18 (31)
Alcohol
No drinking, (%)
110 (85)
62 (87)
48 (81)
0.487
Ex-drinking and current drinking, (%)
20 (15)
9 (13)
11 (19)
Family history of IBD, (%)
2 (2)
0 (0)
2 (3)
0.204
Albumin (g/dL), mean (SD)
3.96 (0.66)
3.84 (0.65)
4.12 (0.66)
0.027
CRP (mg/dL), mean (SD)
1.9 (3.99)
2.18 (3.95)
1.6 (4.05)
0.429
ESR (mm/hour), mean (SD)
21.65 (23.06)
24.91 (26.38)
18.51 (19.04)
0.142
Comorbidity
HBV carrier, (%)
15 (12)
8 (11)
7 (12)
1.000
Old TB
1 (1)
1 (1)
0 (0)
1.000
Conventional medicines
Steroids, (%)
107 (82)
57 (80)
50 (85)
0.665
5-ASAs, (%)
125 (96)
66 (93)
59 (100)
0.063
Immunomodulators, (%)
73 (56)
48 (68)
25 (42)
0.007
Biological agent selection
Adalimumab, (%)
124 (95)
69 (97)
55 (93)
0.410
Infliximab, (%)
7 (5)
6 (8)
1 (2)
0.126
Vedolizumab, (%)
11 (8)
6 (8)
5 (8)
1.000
Golimumab, (%)
2 (2)
0 (0)
2 (3)
0.204
5-ASAs: 5-aminosalicylic acids; BMI: body mass index; CD: Crohn’s disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HBV: hepatitis B virus; IBD: inflammatory bowel disease; TB: tuberculosis; UC: ulcerative colitis.
